Jason Napodano Quotes
The study certainly isn't ideal for Pfizer. There were some positives for Pfizer, and they will have to go out and do some education (on them). 
Tweet
Study | Ideal | Pfizer | Positives | Education |
comments powered by Disqus
I think Bristol-Myers is an excellent takeover candidate. It has a bloated cost structure and some really good mid- to late-stage products.
- Jason Napodano
